MedTrace Logo

CAP-Ketamine for Antidepressant Resistant PTSD

NCT02655692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2022-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

Conditions

Interventions

DRUG

Ketamine

FDA approved anesthetic medication with rapid acting antidepressant effects.

DRUG

Placebo/Saline

This is a saline placebo/non-active solution.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    collaborator OTHER

  • Brooke Army Medical Center

    collaborator FED

  • Minneapolis Veterans Affairs Medical Center

    collaborator FED

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • John H. Krystal, MD · VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-18
Primary Completion
2020-07-01
Completion
2020-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655692 on ClinicalTrials.gov